We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Enzyme Inhibitor Blocks Respiratory Virus Replication

By LabMedica International staff writers
Posted on 29 May 2018
Print article
Image: The novel molecule IMP-1088 (yellow) blocks human NMT (blue), a protein essential for the cold virus to assemble the geometric capsid shell, which encloses its RNA genome (green) (Photo courtesy of Imperial College London).
Image: The novel molecule IMP-1088 (yellow) blocks human NMT (blue), a protein essential for the cold virus to assemble the geometric capsid shell, which encloses its RNA genome (green) (Photo courtesy of Imperial College London).
A recently crafted drug molecule has proven to be a potential candidate for treatment of the viruses responsible for the common cold and other respiratory diseases.

Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of complications in asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

In an effort to combat respiratory viruses, investigators at Imperial College London (United Kingdom) synthesized the compound IMP-1088, a picomolar dual inhibitor of the human enzymes N-myristoyltransferases NMT1 and NMT2. N-myristoyltransferase catalyzes the transfer of myristate - a rare 14-carbon saturated fatty acid, which is attached by an amide linkage to the N-terminal glycine residue of cellular and viral proteins with diverse functions - from CoA to proteins.

Crystal structures and other evidence had revealed that two inhibitors, which the investigators had identified early in their studies, targeted different sites on the human enzymes. They used a fragment-based drug design approach to combine the two inhibitors and structure-guided design to optimize the combination agent’s drug properties.

The investigators reported in the May 14, 2018, online edition of the journal Nature Chemistry that that inhibition of the myristoylation of a specific virus-encoded protein (VP0) by IMP-1088 potently blocked a key step in viral capsid assembly, to deliver a low nanomolar antiviral activity against multiple RV strains, poliovirus, and foot and-mouth disease virus. The compound was found to be nontoxic to cell cultures.

"The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and COPD. A drug like this could be extremely beneficial if given early in infection, and we are working on making a version that could be inhaled, so that it gets to the lungs quickly," said senior author Dr. Edward W. Tate, professor of chemical biology at Imperial College London.

Related Links:
Imperial College London

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.